Cardinal Health, Inc. $CAH Stock Bought by NFSG Corp

NFSG Corp lifted its holdings in Cardinal Health, Inc. (NYSE:CAH) by 85,325.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 6,834 shares of the company’s stock after acquiring an additional 6,826 shares during the quarter. NFSG Corp’s holdings in Cardinal Health were worth $1,449,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Downshift Financial LLC raised its stake in Cardinal Health by 3,666.7% in the 3rd quarter. Downshift Financial LLC now owns 113 shares of the company’s stock worth $25,000 after purchasing an additional 110 shares in the last quarter. Investors Research Corp bought a new stake in Cardinal Health in the 2nd quarter valued at about $29,000. Maryland Capital Advisors Inc. grew its position in shares of Cardinal Health by 12,600.0% during the 3rd quarter. Maryland Capital Advisors Inc. now owns 127 shares of the company’s stock worth $28,000 after purchasing an additional 126 shares in the last quarter. Allied Private Wealth LLC acquired a new position in shares of Cardinal Health during the 2nd quarter worth approximately $30,000. Finally, NBH Bank acquired a new position in shares of Cardinal Health during the 2nd quarter worth approximately $31,000. 87.17% of the stock is owned by institutional investors.

Cardinal Health Stock Up 2.3%

CAH opened at $253.44 on Friday. The stock has a market capitalization of $58.69 billion, a price-to-earnings ratio of 35.05, a P/E/G ratio of 1.49 and a beta of 0.50. Cardinal Health, Inc. has a twelve month low of $152.46 and a twelve month high of $258.30. The company has a 50-day simple moving average of $234.20 and a 200 day simple moving average of $222.00.

Cardinal Health (NYSE:CAH) last released its earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.42 by $0.49. The firm had revenue of $63.67 billion for the quarter, compared to analyst estimates of $65.15 billion. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned $2.08 EPS. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Sell-side analysts anticipate that Cardinal Health, Inc. will post 12.55 EPS for the current fiscal year.

Cardinal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 15th. Investors of record on Thursday, October 1st were paid a $0.5158 dividend. This represents a $2.06 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Thursday, October 1st. Cardinal Health’s dividend payout ratio (DPR) is 28.49%.

Insiders Place Their Bets

In other Cardinal Health news, insider Michelle D. Greene sold 11,650 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.72, for a total transaction of $2,746,138.00. Following the completion of the sale, the insider directly owned 10,330 shares in the company, valued at $2,434,987.60. This represents a 53.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Deborah Weitzman sold 7,354 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.45, for a total value of $1,731,499.30. Following the sale, the chief executive officer owned 77,901 shares of the company’s stock, valued at $18,341,790.45. The trade was a 8.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 210,271 shares of company stock valued at $49,626,657 over the last three months. 0.12% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

CAH has been the subject of a number of analyst reports. UBS Group lifted their price target on shares of Cardinal Health from $274.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Wells Fargo & Company increased their price target on Cardinal Health from $245.00 to $277.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Bank of America increased their price target on Cardinal Health from $240.00 to $260.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. Weiss Ratings upgraded Cardinal Health from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Finally, Royal Bank Of Canada assumed coverage on Cardinal Health in a report on Wednesday, August 19th. They issued an “outperform” rating and a $276.00 price objective for the company. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Cardinal Health has a consensus rating of “Moderate Buy” and a consensus target price of $266.56.

Cardinal Health Profile

Cardinal Health, Inc is a healthcare services and products company that supports pharmacies, hospitals, ambulatory surgery centers, physician offices and other healthcare providers. Its operations are primarily organized into Pharmaceutical and Medical segments.

The Pharmaceutical segment distributes branded, generic, specialty and over-the-counter medicines, as well as consumer health products. It also provides services related to specialty pharmaceuticals, pharmaceutical sourcing, nuclear and precision health products, and data and analytics for pharmaceutical manufacturers and healthcare organizations.

The Medical segment distributes medical and surgical products, including gloves, apparel, incontinence supplies, laboratory products and other essential items.